|
| ID | Sample size (I/C) | Age (I/C) | Surgery | Intervention methods | Controlled methods | Treatment course | Following up | Outcomes |
|
| Bi and Wang 2013 | 23/19 | Unreported | N/A | Dan’e-fukang, 10 g each time, 2 times a day, taken 14 days before menstruation | Mifepristone, 12.5 ng each time, 2 times a day | 3 months | N/A | Dysmenorrhea, safety |
| Cai et al. 2004 | 343/160 | 35 (16–48) | N/A | Dan’e-fukang, 10 g each time, 2 times a day, taken 15 days before menstruation | Danazol, 200 mg each time, 3 times a day | 3 months | N/A | Effective rate |
| Chen WZ 2010 | 62/58 | I: 35.0 ± 3.3; C: 34.0 ± 3.1 | Postoperation | Dan’e-fukang, 10 g, 1 time a day; Diphereline 3.75 mg intramuscular injection, 28 days once, 3 times totally | Diphereline, 3.75 mg intramuscular injection, 28 days once, 6 times totally | 6 months | 12 months | Effective rate, rate of pregnancy, recurrence rate, safety |
| Chen 2009 | 40/38 | I: 30.4 ± 10.0; C: 33.4 ± 8.7 | Postoperation | Dan’e-fukang, 10 g each time, 3 times a day | Gestrinone, 2.5 mg each time, 2 times a week | 6 months | 18 months | Rate of pregnancy, recurrence rate, safety |
| X. H. Chen and X. L. Chen 2010 | 55/55 | I: 36.88 ± 5.96; C: 34.13 ± 7.25 | N/A | Dan’e-fukang, 15 g each time, 2 times a day, taken 10 days before menstruation, keep taken in menstrual period | Gestrinone, 2.5 mg each time, 2 times a week | 3 months | N/A | Effective rate, dysmenorrhea, safety |
| Chen 2011 | 60/60 | I: 34 (21–45); C: 31 (19–46) | N/A | Dan’e-fukang, 15 g each time, 2 times a day | Gestrinone, 2.5 mg each time, 2 times a week | 6 months | N/A | Effective rate, safety |
| Di and Lou 2007 | 31/29 | Unreported | N/A | Dan’e-fukang, 10 g each time, 2 times a day, taken 10 days before menstruation | Mifepristone, 12.5 mg each time, 2 times a day | 3 months | N/A | Effective rate, safety |
| Huang 2012 | 64/64 | I: 29.15 ± 4.65; C: 28.95 ± 4.85 | N/A | Dan’e-fukang, 10 g each time, 2 times a day | Danazol, 200 mg, Mifepristone, 12.5 mg each time, 3 times a day | 2 months | N/A | Effective rate, CA125, safety |
| Huang et al. 2013 | 38/38 | I: 37.4 ± 4.5; C: 34.5 ± 5.1 | Postoperation | Dan’e-fukang, 15 g each time, 2 times a day; Mifepristone, 10 mg/d, 1 time a day | Mifepristone, 10 mg, 1 time a day | 3 months | N/A | Effective rate, recurrence rate, safety |
| Jin et al. 2011 | 60/60 | I: 34 (21–45); C: 31 (19–46) | N/A | Dan’e-fukang, 15 g each time, 2 times a day, taken 15 days before menstruation | Gestrinone, 2.5 mg each time, 2 times a week | 6 months | N/A | Effective rate, safety |
| Jin et al. 2013 | 56/56 | I: 32.6 ± 4.7; C: 31.2 ± 4.3 | N/A | Dan’e-fukang, 15 g each time, 2 times a day, taken 10 days before menstruation | Danazol, 200 mg each time, 3 times a day | 3 months | N/A | Effective rate, safety |
| Li and Zhu 2010 | 45/45 | 18–44 | N/A | Dan’e-fukang, 15 g each time, 2 times a day, taken 10 days before menstruation | Mifepristone, 12.5 mg each time | 6 months | N/A | Effective rate |
| 45/45 | Dan’e-fukang, 15 g each time, 2 times a day, taken 10 days before menstruation | Marvelon, 2.5 mg, 1 time a day |
| Li 2012 | 47/47 | 36.6 (22–48) | Postoperation | Dan’e-fukang, 10 g each time, 2 times a day | Gestrinone, 2.5 mg each time, 2 times a week | 6 months | N/A | Effective rate, recurrence rate, safety |
| Lin and Fu 2006 | 72/58 | I: 33.8 ± 7.3; C: 34.8 ± 6.1 | N/A | Dan’e-fukang, 15 g each time, 2 times a day, taken 10 days before menstruation | Gestrinone, 2.5 mg each time, 2 times a week | 6 months | 1 year–3 years | Effective rate, CA125, rate of pregnancy, symptom score, safety |
| Shen et al. 2011 | 28/28 | 19–42 | N/A | Dan’e-fukang, 10–15 g each time, 2 times a day; Mifepristone, 6.25 mg, 1 time a day | Mifepristone, 10 mg, 1 time a day | 3 months | 3 months | Dysmenorrhea, safety |
| Shen and Wang 2013 | 96/97 | I: 37.0 ± 6.3; C: 36.7 ± 5.8 | N/A | Dan’e-fukang, 10 g each time, 2 times a day | Gestrinone, 2.5 mg each time, 2 times a week | 6 months | N/A | Effective rate, CA125, safety |
| Tu 2011 | 343/160 | 35 (16–48) | N/A | Dan’e-fukang, 10 g each time, 2 times a day, taken 15 days before menstruation | Danazol, 200 mg, 3 times a day | 3 months | N/A | Effective rate, safety |
| >Wang et al. 2013 | 200/200 | Unreported | N/A | Dan’e-fukang, 10–15 g each time, 2 times a day | Gestrinone, 2.5 mg each time, 2 times a week | 3 months | 1 year | Dysmenorrhea, recurrence rate, safety |
| Wang 2008 | 40/40 | I: 28.15 (19–45); C: 30 (21–43) | N/A | Dan’e-fukang, 10 g each time, 2 times a day, | Gestrinone, 2.5 mg each time, 2 times a week | 3 months | N/A | Effective rate, safety |
| Wang and Hu 2007 | 30/30 | I: 30 ± 3.5; C: 29 ± 4.4 | Postoperation | Dan’e-fukang, 15 g each time, 2 times a day | No treatment | 2 months | 12 months | Effective rate, rate of pregnancy, recurrence rate, safety |
| Wu et al. 2004 | 80/42 | I: 32 (23–41); C: 32.5 (24–40) | N/A | Dan’e-fukang, 10–15 g each time, 2 times a day | Marvelon, taken on the fifth day of menstruation, 1 tablet a day | 3 months | N/A | Effective rate, improvement of symptoms |
| Xiong et al. 2014 | 30/30 | I: 27.3 ± 1.9; C: 29.1 ± 2.7 | Postoperation | Dan’e-fukang, 10 g each time, 2 times a day | Danazol, 200 g each time, 3 times a day | 6 months | 6 months | Effective rate, recurrence rate, safety |
| Xiong and Wang 2012 | 65/55 | I: 34.3, C: 33.8 | N/A | Dan’e-fukang, 15 g each time, taken 10 days before menstruation, 2 times a day | Gestrinone, 2.5 mg each time, 2 times a week | 3 months | 3 months | Effective rate, CA125, rate of pregnancy, safety |
| Xu 2011 | 87/71 | I: 36.21 ± 5.25; C: 36.96 ± 5.31 | N/A | Dan’e-fukang, 15 g each time, taken 10 days before menstruation, 2 times a day | Gestrinone, 2.5 mg each time, 2 times a week | 3 months | 3 months | Effective rate, dysmenorrhea, CA125, rate of pregnancy, safety |
| Xu et al. 2013 | 72/72 | 25–49 | N/A | Dan’e-fukang, 15 g each time, 2 times a day | Gestrinone, 2.5 mg each time, 2 times a week | 3 months | N/A | Effective rate, dysmenorrhea, safety |
| Yang 2015 | 91/92 | I: 37.01 ± 6.3; C: 36.7 ± 5.8 | N/A | Dan’e-fukang, 10 g each time | Gestrinone, 2.5 mg each time, 2 times a week | 6 months | N/A | Effective rate, CA125, rate of pregnancy, safety |
| Yang et al. 2010 | 37/34 | Unreported | Postoperation | Dan’e-fukang, 10 g each time, 2 times a day | Mifepristone, 10 mg each time, 1 time a day | 6 months | N/A | Effective rate, rate of pregnancy, recurrence rate, safety |
| Yao 2005 | 60/60 | I: 28.5 (23–40); C: 30 (21–43) | N/A | Dan’e-fukang, 10 g each time, 2 times a day, taken 10 days before menstruation | Gestrinone, 2.5 mg each time | 6 months | N/A | Effective rate, safety |
| Yao et al. 2013 | 60/60 | 36 (18–50) | N/A | Dan’e-fukang, 15 g each time, 2 times a day, taken 15 days before menstruation | Danazol, 200 mg each time, 3 times a day | 3 months | N/A | Effective rate |
| Yin et al. 2014 | 60/60 | I: 34.9 ± 7.1; C: 35.9 ± 5.9 | N/A | Dan’e-fukang, 10 g each time, 2 times a day | Intrauterine placed Mirena | 9 months | N/A | Effective rate |
| Zhang et al. 2010 | 60/30 | 33.4 (20–53) | N/A | Dan’e-fukang, 10–15 g each time, 2 times a day, taken 10 days before menstruation | Gestrinone, 2.5 mg each time, 2 times a week; | 3 months | N/A | Dysmenorrhea, safety |
| 60/20 | Dan’e-fukang, 10–15 g each time, 2 times a day, taken 10 days before menstruation | Placebo |
| Zhang and Li 2008 | 53/50 | 36 (18–50) | N/A | Dan’e-fukang, 10 g each time, 2 times a day | Danazol, 200 mg each time, 3 times a day | 3 months | N/A | Effective rate, safety |
| Zhang and Li 2007 | 40/35 | I: 33.0 ± 2.7; C: 34.0 ± 5.4 | Postoperation | Dan’e-fukang, 10 g each time, 2 times a day | Gestrinone, 2.5 mg each time, 2 times a week | 3 months | N/A | Effective rate, rate of pregnancy, safety |
| Zhang and Ren 2008 | 112/43 | 34.6 (19–48) | N/A | Dan’e-fukang, 15 g each time, 2 times a day, | Danazol, 200 mg each time, 2 times a day | 3 months | 3 months | Effective rate |
| Zhao 2013 | 75/75 | I: 35.9 ± 5.68; C: 36.7 ± 6.8 | Postoperation | Dan’e-fukang, 10 g each time, 2 times a day | Gestrinone, 2.5 mg each time, 2 times a week | 7 months | N/A | Effective rate, recurrence rate, safety |
| Zhao et al. 2011 | 18/20 | 21–42 | Postoperation | Dan’e-fukang, 15 g each time, 2 times a day, taken 10 days before menstruation | Gestrinone, 2.5 mg each time, 2 times a week | 6 months | 1 year | Effective rate, hormone level |
| X. H. Zheng and J. B. Zheng 2015 | 105/105 | I: 36.25 ± 4.35; C: 36.05 ± 4.01 | N/A | Dan’e-fukang, 15 g each time, 2 times a day | Gestrinone, 2.5 mg/d, the first taken on the first day of menstruation, the second taken on the fourth day of menstruation | 3 months | N/A | Effective rate, dysmenorrhea, CA125, rate of pregnancy, safety |
| Zhu 2010 | 50/41 | I: 36.19 ± 4.66; C: 37.34 ± 4.98 | N/A | Dan’e-fukang, 15 g each time, 2 times a day | Gestrinone, 2.5 mg each time, 2 times a week | 3 months | 3 months | Dysmenorrhea, safety |
| Zhu 2013 | 32/32 | 35.8 ± 2.3 | N/A | Dan’e-fukang, 10 g each time, 2 times a day | Gestrinone, 2.5 mg each time, 2 times a week | 6 months | N/A | Effective rate, CA125, safety |
| Zhu and Lei 2010 | 50/50 | 36.19 ± 4.84 | Postoperation | Dan’e-fukang, 10 g each time, 2 times a day, taken 1 week after operation | Gestrinone, 2.5 mg each time, 2 times a week, taken 1 week after operation | 6 months | 3 years | Effective rate, dysmenorrhea, recurrence rate, improvement of symptoms |
|
